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Acute respiratory distress syndrome (ARDS) is considered a major cause of 
death in the world. ARDS is defined by life-threatening pulmonary edema and 
hypoxemia with a mortality rate of up to 40%. Recent advances in understating 
cellular aspects of the syndrome have shed light on possible new treatments 
and reduction of mortality. Toll-like receptors (TLRs) are pattern recognition 
receptors (PRRs) involved in adaptive and innate immunity. They are present 
in the alveoli and their activation can lead to inflammatory responses and 
finally acute lung injury. Among them, Toll-like receptor 4 (TLR4) is 
abundantly available on the epithelial cells of the alveoli and also on resident 
monocytes. TLR4 is one of the players that can promote alveolar damages 
during ARDS. Here, we focus on the TLR4 role in ARDS pathophysiology. 
We also present the potential therapies for the syndrome based on TLR4 
inhibition. 
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Introduction 
The initial definition of acute respiratory distress 
syndrome (ARDS) was developed by the American-
European Consensus Conference (AECC) in 1994. 
However, there were some issues bout this definition, 
and years later in 2011 a new definition was developed 
by the European Society of Intensive Care Medicine 
endorsed by the American Thoracic Society and the 
Society of Critical Care Medicine, which was 
considered as Berlin Definition; the latter is more 
feasible and well-known term. ARDS definition by 
Berlin criteria includes radiologic changes including 
pulmonary edema and bilateral patchy infiltration in 
chest X-ray or pulmonary CT scan with moderate to 
severe impairment of blood oxygenation. The amount 
of arterial oxygen tension to the fraction of inspired 
oxygen content (PaO2/FiO2) is also included (1, 2). 
 mild (200mmHg<Pao2/Fio2≤300mmHg) 
 moderate (100mmHg<Pao2/Fio2≤200mmHg) 
 severe (Pao2/Fio2≤100mmHg) 
Besides, there are 4 ancillary variables for severe 
ARDS: 
 radiographic a severity 
 respiratory system compliance ≤40ml/cmH2O 
 positive end-expiratory pressure ≥10cm H2O 
 the corrected expired volume per minute ≥10 l/min 
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Toll-Like Receptor 4 (TLR) Structure 
All Toll-Like Receptors (TLR) have a glycoprotein 
structure weighed between 90 and 150 kDa (3). In 
terms of the structure, TLR4 is a member of the large 
interleukin receptor family (IL-IR). TLR4 consists of 
three components: 
1. The outer part of the N-terminal cell is composed of 
two components of leucine-rich repeat (LRR) and 60 
amino acids cysteine. 
2. Membrane part 
3. The C-terminal intracellular part that is IL-
IRhomolog. 
To bind to lipopolysaccharides (LPS), TLR4 needs a 
co-receptor called MD-2. After stimulation, the TLR4-
MD-2 complex forms a dimer and makes a cellular 
response. TLR4 can bind to LPS in both hydrophobic 
and hydrophilic ways (4). 
 
Ligands 
Many studies have been carried out on TLR4-
stimulating factors. There are two ligand classes for 
TLR4: exogenous and endogenous. Endogenous 
ligands, also called damage-associated molecular 
pattern (DAMP), are not produced under physiological 
conditions; but rather are primarily released from 
degrading and dying cells. The most important 
endogenous ligands are heat shock proteins (HSPs); 
and fibrinogen. Exogenous ligands, also called 
pathogen-associated molecular patterns (PAMP), are 
released from microorganisms. These most 
importantly include LPS, peptidoglycan, and 
lipoteichoic acid compounds (5,6). 
 
Expression and Signal Transduction 
Overall, TLR4 is expressed in many tissues but more 
importantly, and with varying degrees, it is present on 
macrophages, dendritic cells, and lymphocytes (7,8). 
The CD14 marker, which is mainly found on the 
surface of the monocytes, transfers ligands like LPS to 
TLR4. Following stimulation, TLR4 forms a dimer; 
then the cellular response is initiated. The intracellular 
signals initiated by TLR4 are divided into two Myd88 
protein-dependent and Myd88 protein-independent 
categories. In the dependent form, which initiates 
earlier, after Myd88 activation, downstream kinase 
enzymes such as IRAK4 are activated (9). 
Subsequently, IRAK4 activates another enzyme called 
IRAF6. Activation of IRAF6 activates the Nuclear 
factor-kappa B transcription factor (NF-κB) and MAP 
kinase pathway. NF-κB entry into the cell nucleus and 
activation of the MAP kinase pathway produces 
inflammatory cytokines like TNF-α, IL1-β, and IL-6 
(9-10). 
The second pathway, Myd88-protein-independent, 
starts later and induces the downstream kinases such as 
TRAM, TRIF, and TRAF are activated. These 
activations will result in translocation of NF-κB and 
IRF3 to the nucleus (10,11). 
 
TLR4 in ARDS 
TLR4 is involved in several inflammatory conditions; 
from ischemic heart disease to ventilator-associated 
pneumonia (VAP) (11-14). Normally, there are two 
types of alveolar epithelial cells; alveolar type I (ATI) 
and alveolar type II (ATII). AT1 cells are frequently 
present and can be easily injured. Damage to type I 
cells causes fluid entry into the alveoli that can disrupt 
the normal alveolar clearance. The ATII cells are 
responsible for surfactant secretion, a critical factor 
that decreases the alveolar tension. Besides, ATII cells 
are involved in ion transportation. ATII cells are low 
in number yet are more resistant to the damages (13-
15). Both alveolar epithelial cells and capillary 
vascular cells can be involved in the syndrome. 
However, endothelial damages are more common. In 
ARDS, due to increased permeability of the capillaries, 
there is a leakage of fluids and proteins to the 
interstitium. After that, there is an entry of fluids, red 
cells, and neutrophils into the alveolar space across the 
damaged epithelial cells. Interstitial and alveolar 
edema is usually seen in the exudative phase of ARDS 
(16,17). TLR4 is present on the alveolar macrophages 
and the alveolar epithelial cells. During ARDS 
propagation, TLR4 recognizes important ligands like 
hyaluronan, LPS, heat shock proteins, and also high 
mobility group box-1(HMGB) protein (17-19). As 
mentioned early, activation of TLR4 results in the 
production of pro-inflammatory cytokines which can 
promote the degree of injuries. During recent years 
many works have put their efforts to elucidate TLR4's 
exact role in ARDS. Of note, present data are mainly 
from experimental studies in mice and rats. A work by 
Deng showed that there is a considerable amount of 
TLR4 expression on alveolar macrophages; which can 
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be overexpressed by recombinant human HMGB-1. 
Sprague-Dawley rats were used for the induction of 
acute lung injury by rhHMGB-1 (19, 20). Another 
study provided evidence for TLR4 and TLR3 cross-
talk in murine acute lung injury (20, 21). A work by 
Wu indicated that there was a marked reduction in IL-
1β, and TNF-α production in TLR4 knocked down 
mice (21-23). This study indicated that LPS could not 
initiate vast inflammatory responses when TLR4 was 
silenced. Interestingly a fresh study in mice showed 
that angiotensin-converting enzyme 2 (ACE2) was 
able to attenuate the inflammatory responses following 
LPS induced lung injury (22-23). Taken together, 
many experimental investigations have provided a 
wealth of body of evidence about the TLR4 role in 
ARDS. Besides, limited works have been performed to 
explore TLR4 involvement and TLR4 inhibition in 
human ARDS. Go’s study was one of the first studies 
which proved TLR4 overexpression on epithelial cells 
of patients with idiopathic interstitial pneumonia (23-
25). Of note, some investigations have reported the role 




Evidence from different experimental and clinical 
investigations has shown that inhibition of TLR4 or its 
downstream pathways is useful in reducing 
inflammation. The study by Li et al. revealed that 
Celastrol, known as an anti-tumor compound in 
Chinese traditional medicine, may decrease TLR4 
expression and reduce matrix metalloproteinase 
production in an experimental rheumatoid arthritis 
model in rats; moreover, coumarin derived from the 
plant Urtica Dentate Hand has been shown effective in 
reducing TLR4 expression and downregulating its 
downstream pathways in rats with type 1 autoimmune 
diabetes (25-27). In addition to the above herbal 
compounds, many antibodies have been made against 
TLR4. Eritoran is one of the initial antibodies 
developed against TLR4. The efficacy of this 
compound in the prevention of bacterial and viral 
sepsis in experimental models of inflammation has 
been successfully demonstrated; in conducted clinical 
trials, eritoran has not declined mortality from severe 
infection and septic shock (27-29). The last class of 
TLR4 inhibitors is recently studied small molecule 
inhibitors (SMIs). These molecules may enter the cells 
and affect the signaling pathways. Through inhibiting 
intracellular kinases, CPG-52364 inhibits the rapid 
production of cytokines. RDP58 inhibits the 
intracellular interaction of Myd88, IRAK4, and 
TRAF6. RDP58 has been associated with clinical 
improvement in experimental models of autoimmune 
encephalomyelitis; also, the results of some clinical 
trials confirm the efficacy of this compound in treating 
ulcerative colitis and in kidney transplantation (29-31). 
CLI-095 (also known as TAK-242), is another small 
molecule that has been shown as an efficacious agent 
for blocking human and murine TLR4 signaling and 
hence reducing cytokine production (31-33). Recent 
studies have shown that inhibiting TLR4 using TAK-
242 can reduce the onset and development of sepsis in 
individuals who are at risk and there has already been 
a successful phase 1 clinical trial about TAK-242 
effects in healthy volunteers; while TAK-242 prodrugs 
are currently under design for inhibition of TLR-4 and 
can be clinically tested (32-34). Interestingly, some 
Chinese traditional compounds have been found to 
reduce the alveolar and macrophage expression of 
TLR4 in mice or rat model of ARDS. Such compounds 
as Glycyrrhizin, Ruscogenin, Polygonatum sibiricum, 
Madecassoside, and Nuciferine (34-39). Bedsides, 
Nano-particles that can antagonize TLR4 are 
emerging. However, there are limited clinical 
investigations and their long term effects remain to be 
defined (39-41). Interestingly, a recent study provided 
evidence for the beneficial effects of dexmedetomidine 
in lung injury. Xue et al showed that preconditioning 
with dexmedetomidine (DEX) was able to reduce the 
TLR4 pathway in mice with lung injury. DEX could 
remarkably decrease levels of TNF- α, IL-1, and IL-6. 
It could decrease neutrophil infiltration, as well. The 
anti-inflammatory effects of DEX can be partially 
explained by α -2 adrenoceptor activation (40,41). 
 
Conclusion 
Many studies have demonstrated the role of TLR4 in 
ARDS. Like a double-edged sword, TLR4 acts both as 
a barrier against infectious diseases and as a 
predisposing factor to inflammatory damages. The 
main challenge is how to inhibit TLR4 with minimal 
effects on the immune system. Future studies and the 
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introduction of new drugs may overcome this 
challenge and provide deeper understandings of the 
effects of TLR4 inhibition. 
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